v3.25.4

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 28,492	$ 17,198
Investments	134,777	131,864
Restricted cash	670	285
Prepaid expenses and other current assets	3,015	3,629
Total current assets	166,954	152,976
Restricted cash	0	385
Property and equipment, net	159	385
Operating lease right-of-use assets	1,082	2,133
Total assets	168,195	155,879
Current liabilities:
Accounts payable	2,215	4,786
Accrued expenses	16,844	5,426
Operating lease liabilities, current	1,633	1,606
Total current liabilities	20,692	11,818
Operating lease liabilities, noncurrent	0	1,633
Total liabilities	20,692	13,451
Stockholders' equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding at December 31, 2025 and December 31, 2024	0	0
Common stock, $0.0001 par value; 300,000,000 shares authorized,17,611,511 and 12,179,482 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	2	1
Additional paid-in capital	702,984	619,285
Accumulated deficit	(555,430)	(476,893)
Accumulated other comprehensive loss	(53)	35
Total stockholders’ equity	147,503	142,428
Total liabilities and stockholders’ equity	$ 168,195	$ 155,879

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Corbus Pharmaceuticals Holdings, Inc. 10-K